Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ursodeoxycholic acid (UDCA) combined with vitamin E is a therapeutic combination used primarily for treating nonalcoholic steatohepatitis (NASH) and other liver conditions. UDCA is a hydrophilic bile acid that protects hepatocytes and cholangiocytes from bile acid-induced damage, reduces oxidative stress, and has choleretic effects. It works by displacing more toxic bile acids, protecting against reactive oxygen species (ROS), and stimulating anti-apoptotic pathways. Vitamin E functions as an antioxidant, complementing UDCA's hepatoprotective effects. Clinical studies have shown that this combination significantly improves liver function tests in long-term use and is very well tolerated. The combination has been studied in various liver conditions including NASH and methotrexate-induced liver injury in pediatric leukemia patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ursodeoxycholic acid + vitamin e.